BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28295504)

  • 21. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic hypogonadism.
    Chillarón JJ; Fernández-Miró M; Albareda M; Fontserè S; Colom C; Vila L; Pedro-Botet J; Flores Le-Roux JA
    Endocr J; 2016 Sep; 63(9):849-855. PubMed ID: 27452372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Testosterone Undecanoate Pills improves insulin resistance in type-2 diabetes men with hypogonadism].
    DI HJ; Fan YF; Zhang HF; Liu KM; Liu C
    Zhonghua Nan Ke Xue; 2017 Jun; 23(6):517-521. PubMed ID: 29722943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.
    Shigehara K; Konaka H; Kato Y; Iijima M; Nakashima K; Kawaguchi S; Nohara T; Izumi K; Namiki M; Mizokami A
    Int J Impot Res; 2019 Jan; 31(1):25-30. PubMed ID: 30135606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels.
    Pelusi C; Fanelli F; Baccini M; Triggiani V; Bartolomeo N; Carbone MD; De Pergola G; Di Dalmazi G; Pagotto U; Pasquali R; Giagulli VA
    Clin Endocrinol (Oxf); 2020 Jan; 92(1):38-45. PubMed ID: 31677181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism).
    Saad F
    Adv Exp Med Biol; 2017; 1043():527-558. PubMed ID: 29224109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P;
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
    Saad F; Doros G; Haider KS; Haider A
    Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
    Saad F; Yassin A; Almehmadi Y; Doros G; Gooren L
    Aging Male; 2015; 18(3):164-8. PubMed ID: 26075537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Arch Androl; 2007; 53(6):353-7. PubMed ID: 18357966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMAS position statement: Testosterone replacement therapy in the aging male‏.
    Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
    Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
    Kapoor D; Goodwin E; Channer KS; Jones TH
    Eur J Endocrinol; 2006 Jun; 154(6):899-906. PubMed ID: 16728551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus.
    Gopal RA; Bothra N; Acharya SV; Ganesh HK; Bandgar TR; Menon PS; Shah NS
    Endocr Pract; 2010; 16(4):570-6. PubMed ID: 20150021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.